Indaptus Therapeutics (NASDAQ:INDP) Trading Down 5.7% – Here’s Why

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) traded down 5.7% on Wednesday . The company traded as low as $7.22 and last traded at $7.26. 5,423 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 13,485 shares. The stock had previously closed at $7.70.

Indaptus Therapeutics Stock Performance

The stock has a market capitalization of $4.14 million, a P/E ratio of -0.17 and a beta of 1.14. The business has a fifty day simple moving average of $10.24 and a 200-day simple moving average of $15.30.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($8.96) EPS for the quarter, beating analysts’ consensus estimates of ($11.48) by $2.52. On average, sell-side analysts anticipate that Indaptus Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.